Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

A new study is reviving hope that a twice-daily pill can slow down Alzheimer's in people whose genes put them at high risk ...

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

An underdog Alzheimer's pill, ALZ-801, showed promise in a subgroup of mild cognitive impairment patients, slowing decline by ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...

Female sex at birth, age of 65 years or older, and 32 specific medications were identified as factors for drug-related candidiasis.

Antibody-based drugs often become too thick to be injected at high concentrations. Now, new research can explain why this ...